Three Clinical Studies Demonstrating Safety and Efficacy of Treatment for Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) in Adults

This supplement is sponsored by Salix Pharmaceuticals.
August 14, 2018|Clinician Reviews

Click to read supplement.   

In this supplement to Clinician Reviews, Christine Frissora, MD, provides an overview of the burdens that patients with IBS-D experience. Three clinical efficacy and safety studies surrounding an FDA-approved treatment are also examined.

Topics include:

,
  • IBS-D diagnosis and treatment challenges
  • The role of microbial imbalance and altered gut microbiota
  • A treatment option for relief of IBS-D symptoms

Click to read supplement. 

XIFI.0273.USA.18